Tesamorelin vs CJC-1295: The Visceral Fat Myth Nobody Explains

In this insightful video, we delve into the comparison between Tesamorelin and CJC-1295, two peptides often discussed in the context of fat loss and muscle gain. The speaker highlights the common myths surrounding visceral fat and how these peptides interact with the body. Tesamorelin is primarily used to reduce abdominal fat in HIV patients, while CJC-1295 is known for its growth hormone-releasing properties. The video aims to clarify misconceptions about these substances and their efficacy in fat loss, particularly focusing on visceral fat.

​

The presentation emphasizes the importance of understanding the mechanisms at play when using these peptides. It explains how visceral fat is different from subcutaneous fat and why targeting it can be beneficial for health. The speaker also discusses potential side effects and the necessity of medical supervision when using these substances. Overall, the video serves as a guide for those considering these peptides, urging them to look beyond the myths and understand the science behind fat loss.

1. Tesamorelin is used to reduce abdominal fat, especially in HIV patients.
2. CJC-1295 promotes growth hormone release but has different uses.
3. Visceral fat differs from subcutaneous fat in health impact.
4. Understanding peptide mechanisms is crucial for effectiveness.
5. Medical supervision is recommended for peptide use.